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Dr Gosta Pettersson (Cleveland, Ohio). I represent myself and
Dr Stewart, who was the original discussant on this report.
I congratulate you for a nice presentation. I congratulate the group
for having put together this registry.
The inclusiveness is really the strength of the study, it represents
a real world experience. I am, however, in doubt about the ability
of this study to distinguish between the AVR and AVS procedures.
Nevertheless, this is a remarkable effort to provide better data on
how we should treat these patients, because there are still many
open questions.
There are 19 centers involved in this registry, but a few centers
have provided a larger number of patients. Is there anything to
learn about the learning curve of the AVS procedure from this?
Dr Coselli. Yes, 2 things. One, if you consider the 30-day data,
there were basically no deaths, no strokes, et cetera. The data from1766 The Journal of Thoracic and Cardiovascular Sur30 days were excellent for the groups from this collection of
institutions. So, consequently, there really was not much in the
way of an impact from a learning curve.
When we considered mortality and valve-related events and
the influence of the institution, we did not find that it was
statistically significant. However, the problem is that with 19
institutions and so many events, it defies a legitimate statistical
evaluation.
Dr Pettersson. The age range was from 4 to 70 years, and most
recently, the percentage of valve-sparing operations approached
100%. Have you identified any limitations, any contraindications
to valve-sparing? Also, what about age? The 4-year-old did not
make it, and you said it was nonvalve-related, but still that is an
interesting question.
Dr Coselli. I do not recall the exact numbers in the very low end
of the pediatric age group, but clearly the 4-year-old patient was a
bit of an outlier. However, when we considered age as a variable
for valve outcome and survival, it was not a statistically significant
factor.
Dr Pettersson.AVS was performed using a number of different
techniques. Did that have any effect on residual AR?
Dr Coselli. No, that did not arise. Again, it had to do with
the total number of events and the wide number of small
variations in technique. So, no, this particular evaluation could
not specifically answer that question.
Dr Pettersson. There were a larger number of bleeding events,
and you separated them into valve-related and nonvalve-related.
A valve-sparing procedure is a significantly longer operation
than just replacing the aortic valve—did that not affect bleeding?
Dr Coselli. That is very interesting. There was increased
complexity with AVS compared with a standard Bentall operation,
removing the patients who had undergone concomitant arch
operations, mitral valve repair, et cetera. Thus, although the
cardiopulmonary bypass times and crossclamp times were longer,
that did not influence the early results or, ultimately, the long-term
results.
Dr Pettersson. My final question relates to the conversions.
At which stage during the operation did the surgeons decide to
abandon trying to save the valve? Conversion after 2.5 hours of
crossclamp time is of great concern.
Dr Coselli. We described this group of 6 patients in our
2011 publication. Surgeons abandoned saving the valve if
post-procedural excessive aortic regurgitation could not be
corrected. While the crossclamp duration before conversion could
not be obtained, the total crossclamp time exceeded 3 hours
for 5 of the 6 patients. Except for one patient who developed
early cardiac tamponade and severe mitral valve regurgitation,
there were no short-term or follow-up complications in this
group.
Dr Pettersson. Thank you, and I also thank the Association for
the privilege to discuss this report.
Dr Marc R. Moon (St Louis, Mo). It is remarkable that
operative mortality only occurred in 2 patients with this very
complex procedure and complex disease. One of the problems
with developing a new innovative technique is that sometimes it
is not reproducible. However, Drs David and Yacoub hit the nail
on the head. They were able to develop an incredibly complex
procedure that is reproducible and safe.gery c June 2014
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DDr Coselli. Agreed.
Dr Hitoshi Ogino (Tokyo, Japan). Thank you very much for an
interesting study and presentation.
My questions are very simple. Unfortunately, some of the
patients developed a stroke during the operation or at the long-term
period. What was the cause of the embolism or stroke? What do
you think about that?
Dr Coselli. That I do not know in detail. There were 4 cases of
early and 2 cases of late embolism that will be described in the
upcoming publication.
Dr Ogino. Another question. Some patients developed AR at
the long-term period. What is the cause of the AR? Have you
analyzed it or did you study it?
Dr Coselli.We are still analyzing that. Again, the imaging core
is with Heidi Connolly at Mayo Clinic, and the numbers were still
small enough for analysis. However, it was basically leaflet
deterioration over time. We know that annular dilatation was not
an issue; thus, it was almost always leaflet deterioration.
But what we are going to have to eventually go back and study
and determine, and I think this is probably more the core of your
question, is whether any of those valve leaflets were prolapsing
below the annulus when the patient left the operating room. We
are still in the process of evaluating those sorts of factors, but do
not have the information for this particular presentation.
Dr Ogino. Thank you very much.The Journal of Thoracic and CarDr Marc R. Moon (St Louis, Mo). What is the planned
long-term follow-up for these patients, and is the study closed
now to accrual?
Dr Coselli. Yes. Accrual of the study has been completed. We
believe it is reasonably powered. It was initially set up as, in
effect, a short-term 3-year follow-up study.
If we can acquire the funding to continue to monitor these
patients and pull the data together at the core sites, we will try to
continue it for at least 10 years, although it would be ideal to
continue for even longer.
This was a unique group of patients because they were all fully
vetted for Marfan syndrome through a single, highly qualified
genetic program, and all the analysis of the imaging was
performed by a single renowned individual.
Thus, the follow-up has beenvery, very goodand the quality of the
data excellent. We will just have to see how this holds up over time.
Dr Leonard N. Girardi (New York, NY). You saw over time
that a move away from AVR occurred, and almost everybody
was undergoing AVS. Did you see a similar move away from
remodeling toward reimplantation?
Dr Coselli.Yes. Only 1 remodeling was performed in the whole
series, and this patient underwent intraoperative conversion.
Almost all these institutions had adopted the inclusion technique
and had moved away from the Yacoub technique very, very early
on, for all the reasons that we accept.diovascular Surgery c Volume 147, Number 6 1767
